Every October, pink ribbons flood communities, symbolizing awareness of breast cancer’s impact. Yet few know that over four decades ago, a groundbreaking discovery could have transformed treatment. In 1977, Dr. Harold W. Manner and his team at Loyola University in Chicago found that Laetrile—also known as Vitamin B17 or amygdalin—combined with enzymes and vitamin A, caused tumors to shrink in 89% of lab cases. Manner’s assertion that “cancer is a metabolic problem” challenged traditional approaches, suggesting mastectomies might no longer be necessary. Instead of revolutionizing care, the research was buried, leaving millions to endure invasive surgeries and toxic therapies while a natural alternative remained hidden. Conservative estimates suggest this suppression may have contributed to the deaths of two million women in America alone since 1977.
Manner’s work built on earlier findings by Dr. Ernst T. Krebs, Jr., who isolated amygdalin from apricot seeds and proposed its targeted effects against cancer cells. By the mid-1970s, Laetrile had gained attention through patients treated by Dr. John A. Richardson in San Francisco, who reported successful outcomes. Manner’s 1977 studies on mice showed tumors regressing significantly, offering a non-toxic alternative to surgery and chemotherapy. However, mainstream medicine dismissed the findings, cutting funding, refusing publications, and labeling Laetrile as unproven.
In 1978, Manner expanded his research to human trials, reporting that 15 women with breast cancer experienced complete tumor disappearance using the same regimen. These results should have sparked a medical revolution but instead triggered backlash from the medical establishment, which ridiculed his work and ignored patient testimonials. Media coverage shifted sharply against Laetrile, with repeated negative narratives overshadowing its potential.
The suppression of this research had lasting consequences. In 1977, the “standard of care” for breast cancer involved radical mastectomies—disfiguring procedures that many now recognize as unnecessary. While women endured these treatments, a promising therapy was quietly erased from public discourse. Critics argue that the medical establishment prioritized profit over patient welfare, stifling alternatives that threatened existing treatment models.
Since 1977, breast cancer has claimed millions of lives, with survival rates improving largely due to early detection rather than better therapies. Advocates for natural treatments point to Manner’s findings as evidence of a missed opportunity—one that could have saved countless lives. As debates over medical ethics persist, the story of Laetrile remains a cautionary tale about the power of science to be shaped by interests beyond patient care.